CC BY 4.0 · Endoscopy 2023; 55(08): 689-698
DOI: 10.1055/a-2040-4042
Original article

Endoscopic full-thickness plication for the treatment of gastroesophageal reflux after peroral endoscopic myotomy: a randomized sham-controlled study

1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
,
Gaurav Patil
1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
,
1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
,
1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
,
Amol Vadgaonkar
1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
,
Sanil Parekh
1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
,
Rajen Daftary
1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
,
Sehajad Vora
1   Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, Maharashtra, India
› Author Affiliations
Trial Registration: Clinical Trials Registry India Registration number (trial ID): CTRI/2019/06/019819 Type of study: Prospective, Randomized Sham Controlled study


Abstract

Background Endoscopic full-thickness plication (EFTP) has shown promising results in gastroesophageal reflux disease (GERD), but its efficacy in GERD after peroral endoscopic myotomy (POEM) is unclear.

Methods In a prospective, randomized trial of post-POEM patients dependent on proton pump inhibitors (PPIs) for documented GERD, patients underwent EFTP (plication to remodel the gastroesophageal flap valve) or an endoscopic sham procedure (positioning of the EFTP device, but no stapling). The primary end point was improvement in acid exposure time (AET) < 6 % (3 months). Secondary end points included improvement in esophagitis (3 months), GERD Questionnaire (GERDQ) score (3 and 6 months), and PPI usage (6 months).

Results 60 patients were randomized (30 in each group). At 3 months, a significantly higher proportion of patients achieved improvement in AET < 6 % in the EFTP group compared with the sham group (69.0 % [95 %CI 52.1–85.8] vs. 10.3 % [95 %CI 0–21.4], respectively). EFTP was statistically superior to sham (within-group analysis) in improving esophageal AET, DeMeester Score, and all reflux episodes (P < 0.001). A nonsignificant improvement in esophagitis was noted in the EFTP group (P = 0.14). Median GERDQ scores (3 months) were significantly better (P < 0.001) in the EFTP group, and the same trend continued at 6 months. A higher proportion of patients in the sham group continued to use PPIs (72.4 % [95 %CI 56.1–88.7] vs. 27.6 % [95 %CI 11.3–43.8]). There were no major adverse events in either group.

Conclusion EFTP improved post-POEM GERD symptoms, 24-hour pH impedance findings with normalization in one-third, and reduced PPI usage at 6 months.

Tables 1 s–6 s, Figs. 1 s–3 s, Appendix 1 s



Publication History

Received: 05 September 2022

Accepted after revision: 01 February 2023

Article published online:
21 March 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Inoue H, Minami H, Kobayashi Y. et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010; 42: 265-271
  • 2 von Renteln D, Fuchs KH, Fockens P. et al. Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study. Gastroenterology 2013; 145: 309-311
  • 3 Shiwaku H, Inoue H, Sasaki T. et al. A prospective analysis of GERD after POEM on anterior myotomy. Surg Endosc 2016; 30: 2496-2504
  • 4 Maydeo A, Patil G. Gastroesophageal reflux disease after peroral endoscopic myotomy: facts and fictions. Int J Gastrointest Interv 2020; 9: 62-66
  • 5 Werner YB, Costamagna G, Swanström LL. et al. Clinical response to peroral endoscopic myotomy in patients with idiopathic achalasia at a minimum follow‐up of 2 years. Gut 2016; 65: 899-906
  • 6 Kumbhari V, Familiari P, Bjerregaard NC. et al. Gastroesophageal reflux after peroral endoscopic myotomy: a multicenter case–control study. Endoscopy 2017; 49: 634-642
  • 7 Teitelbaum EN, Dunst CM, Reavis KM. et al. Clinical outcomes five years after POEM for treatment of primary esophageal motility disorders. Surg Endosc 2018; 32: 421-427
  • 8 Peery AF, Dellon ES, Lund J. et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-1187
  • 9 Iqbal A, Salinas V, Filipi CJ. Endoscopic therapies of gastroesophageal reflux disease. World J Gastroenterol 2006; 12: 2641-2655
  • 10 Repici A, Fuccio L, Maselli R. et al. GERD after per-oral endoscopic myotomy as compared with Heller’s myotomy with fundoplication: a systematic review with meta-analysis. Gastrointest Endosc 2018; 87: 934-943
  • 11 Sanaka MR, Thota PN, Parikh MP. et al. Peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic Heller myotomy in achalasia. Surg Endosc 2019; 33: 2284-2292
  • 12 Zaninotto G, Costantini M, Molena D. et al. Treatment of esophageal achalasia with laparoscopic Heller myotomy and Dor partial anterior fundoplication: prospective evaluation of 100 consecutive patients. J Gastrointest Surg 2000; 4: 282-289
  • 13 Trad KS, Barnes WE, Prevou ER. et al. The TEMPO trial at 5 years: transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surg Innov 2018; 25: 149-157
  • 14 Rothstein R, Filipi C, Caca K. et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: a randomized, sham-controlled trial. Gastroenterology 2006; 131: 704-712
  • 15 Chuttani R, Sud R, Sachdev G. et al. A novel endoscopic full-thickness plicator for the treatment of GERD: a pilot study. Gastrointest Endosc 2003; 58: 770-776
  • 16 Weitzendorfer M, Spaun GO, Antoniou SA. et al. Clinical feasibility of a new full-thickness endoscopic plication device (GERDx) for patients with GERD: results of a prospective trial. Surg Endosc 2018; 32: 2541-2549
  • 17 Jones R, Junghard O, Dent J. et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009; 30: 1030-1038
  • 18 Jobe BA, Kahrilas PJ, Vernon AH. et al. Endoscopic appraisal of the gastroesophageal valve after antireflux surgery. Am J Gastroenterol 2004; 99: 233-243
  • 19 Hill LD, Kozarek RA, Kraemer SJ. et al. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 1996; 44: 541-547
  • 20 Gyawali CP, Kahrilas PJ, Savarino E. et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018; 67: 1351-1362
  • 21 Roman S, Gyawali CP, Savarino E. et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017; 29: 1-15
  • 22 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
  • 23 Wang H, Chow SC. Sample size calculation for comparing proportions. D’Agostino RB, Sullivan L, Massaro J. Wiley encyclopedia of clinical trials [Internet]. Hoboken: John Wiley & Sons, Inc; 2007
  • 24 Corley DA, Katz P, Wo JM. et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125: 668-676
  • 25 Devière J, Costamagna G, Neuhaus H. et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterology 2005; 128: 532-540
  • 26 Schwartz MP, Wellink H, Gooszen HG. et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut 2007; 56: 20-28
  • 27 Schulz KF, Altman DG, Moher D. for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Open Med 2010; 4: 60-68
  • 28 Pleskow D, Rothstein R, Kozarek R. et al. Endoscopic full-thickness plication for the treatment of GERD: five-year long-term multicenter results. Surg Endosc 2008; 22: 326-332
  • 29 Jeansonne 4th LO, White BC, Nguyen V. et al. Endoluminal full-thickness plication and radiofrequency treatments for GERD: an outcomes comparison. Arch Surg 2009; 144: 19-24
  • 30 von Renteln D, Schiefke I, Fuchs KH. et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease using multiple plicator implants: 12-month multicenter study results. Surg Endosc 2009; 23: 1866-1875
  • 31 Koch OO, Kaindlstorfer A, Antoniou SA. et al. Subjective and objective data on esophageal manometry and impedance pH monitoring 1 year after endoscopic full-thickness plication for the treatment of GERD by using multiple plication implants. Gastrointest Endosc 2013; 77: 7-14
  • 32 Kaindlstorfer A, Koch OO, Antoniou SA. et al. A randomized trial on endoscopic full-thickness gastroplication versus laparoscopic antireflux surgery in GERD patients without hiatal hernias. Surg Laparosc Endosc Percutan Tech 2013; 23: 212-222
  • 33 Antoniou SA, Koch OO, Kaindlstorfer A. et al. Endoscopic full-thickness plication versus laparoscopic fundoplication: a prospective study on quality of life and symptom control. Surg Endosc 2012; 26: 1063-1068
  • 34 Domagk D, Menzel J, Seidel M. et al. Endoluminal gastroplasty (EndoCinch) versus endoscopic polymer implantation (Enteryx) for treatment of gastroesophageal reflux disease: 6-month results of a prospective, randomized trial. Am J Gastroenterol 2006; 101: 422-430
  • 35 Kalapala R, Karyampudi A, Nabi Z. et al. Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: results from a randomised, sham controlled trial. Gut 2022; 71: 686-694
  • 36 Inoue H, Shiwaku H, Kobayashi Y. et al. Statement for gastroesophageal reflux disease after peroral endoscopic myotomy from an international multicenter experience. Esophagus 2020; 17: 3-10
  • 37 Jones EL, Meara MP, Schwartz JS. et al. Gastroesophageal reflux symptoms do not correlate with objective pH testing after peroral endoscopic myotomy. Surg Endosc 2016; 30: 947-952
  • 38 Karyampudi A, Nabi Z, Ramchandani M. et al. Gastroesophageal reflux after per-oral endoscopic myotomy is frequently asymptomatic, but leads to more severe esophagitis: a case–control study. United European Gastroenterol J 2021; 9: 63-71
  • 39 Khashab MA. Reflux after peroral endoscopic myotomy. Gastroenterol Hepatol (NY) 2020; 16: 417-419
  • 40 Hernández-Mondragón OV, Solórzano-Pineda OM, González-Martínez M. et al. Gastroesophageal reflux disease after peroral endoscopic myotomy: short-term, medium-term, and long-term results. Rev Gastroenterol Mex (Engl Ed) 2020; 85: 4-11
  • 41 Wei MT, He YZ, Deng XB. et al. Is Dor fundoplication optimum after laparoscopic Heller myotomy for achalasia? A meta-analysis. World J Gastroenterol 2013; 19: 7804-7812